<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Shanghai Fosun Pharmaceutical Group Co Ltd — News on 6ix</title>
<link>https://6ix.com/company/shanghai-fosun-pharmaceutical-group-co-ltd</link>
<description>Latest news and press releases for Shanghai Fosun Pharmaceutical Group Co Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 09 Dec 2025 11:55:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/shanghai-fosun-pharmaceutical-group-co-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68363f0d78dffbe2df14e4cf.webp</url>
<title>Shanghai Fosun Pharmaceutical Group Co Ltd</title>
<link>https://6ix.com/company/shanghai-fosun-pharmaceutical-group-co-ltd</link>
</image>
<item>
<title>Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement</title>
<link>https://6ix.com/company/shanghai-fosun-pharmaceutical-group-co-ltd/news/fosun-pharmas-subsidiary-yao-pharma-115500092</link>
<guid isPermaLink="true">https://6ix.com/company/shanghai-fosun-pharmaceutical-group-co-ltd/news/fosun-pharmas-subsidiary-yao-pharma-115500092</guid>
<pubDate>Tue, 09 Dec 2025 11:55:00 GMT</pubDate>
<description>Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants Pfizer an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 rece</description>
</item>
<item>
<title>Fosun Pharma Announces 2025Q3 Financial Results</title>
<link>https://6ix.com/company/shanghai-fosun-pharmaceutical-group-co-ltd/news/fosun-pharma-announces-2025q3-financial-121100004</link>
<guid isPermaLink="true">https://6ix.com/company/shanghai-fosun-pharmaceutical-group-co-ltd/news/fosun-pharma-announces-2025q3-financial-121100004</guid>
<pubDate>Tue, 28 Oct 2025 12:11:00 GMT</pubDate>
<description>On October 28, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced its financial results for the first three quarters of 2025. In the first three quarters of 2025, Fosun Pharma achieved operating revenue of RMB29,393 million, net profit attributable to shareholders of RMB2,523 million. The revenue from Innovative Drugs grew steadily, exceeding RMB6,700 million in the firs</description>
</item>
<item>
<title>Fosun Pharma Announces 2025 Interim Results</title>
<link>https://6ix.com/company/shanghai-fosun-pharmaceutical-group-co-ltd/news/fosun-pharma-announces-2025-interim-124200431</link>
<guid isPermaLink="true">https://6ix.com/company/shanghai-fosun-pharmaceutical-group-co-ltd/news/fosun-pharma-announces-2025-interim-124200431</guid>
<pubDate>Tue, 26 Aug 2025 12:42:00 GMT</pubDate>
<description>On August 26, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced its operating performance for the first half of 2025 ("the Reporting Period").</description>
</item>
<item>
<title>Fosun Pharma's Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million</title>
<link>https://6ix.com/company/shanghai-fosun-pharmaceutical-group-co-ltd/news/fosun-pharmas-small-molecule-innovative-013600661</link>
<guid isPermaLink="true">https://6ix.com/company/shanghai-fosun-pharmaceutical-group-co-ltd/news/fosun-pharmas-small-molecule-innovative-013600661</guid>
<pubDate>Tue, 12 Aug 2025 01:36:00 GMT</pubDate>
<description>On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement with Expedition Therapeutics Inc.(Expedition) to grant Expedition the rights to develop, manufacture, and commercialize XH-S004, an orally administered dipeptidyl peptidase 1 (DPP-1) inhibitor independently developed by Fosun Pharma, in all regions globally except Chinese Mainland, Hong Kong SAR and Macau SAR. Fosun Pharma will retain the rights to develop, ma</description>
</item>
<item>
<title>Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology</title>
<link>https://6ix.com/company/shanghai-fosun-pharmaceutical-group-co-ltd/news/teva-and-fosun-pharma-enter-into-a-strategic-partnership-to-develop-novel-anti-pd1-il2-therapy-tev-56278-in-immuno-oncology</link>
<guid isPermaLink="true">https://6ix.com/company/shanghai-fosun-pharmaceutical-group-co-ltd/news/teva-and-fosun-pharma-enter-into-a-strategic-partnership-to-develop-novel-anti-pd1-il2-therapy-tev-56278-in-immuno-oncology</guid>
<pubDate>Mon, 16 Jun 2025 13:00:00 GMT</pubDate>
<description>Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", SSE: 600196, HKEX: 02196) today announced that the companies, through their respective subsidiaries, have entered a strategic partnership for the development of investigational TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy. Teva's internally developed ATTENUKINE technology provides a new mechanism of action, potentially offering high efficacy and low toxicity in a broad</description>
</item>
<item>
<title>Fosun Pharma Announces 2024 Annual Results</title>
<link>https://6ix.com/company/shanghai-fosun-pharmaceutical-group-co-ltd/news/fosun-pharma-announces-2024-annual-022900163</link>
<guid isPermaLink="true">https://6ix.com/company/shanghai-fosun-pharmaceutical-group-co-ltd/news/fosun-pharma-announces-2024-annual-022900163</guid>
<pubDate>Wed, 26 Mar 2025 02:29:00 GMT</pubDate>
<description>On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"or "the Group"; Stock Code: 600196.SH, 02196.HK), a leading global pharmaceutical and healthcare company driven by innovation, announced its annual results for the year ended 31 December 2024 ("the Reporting Period").</description>
</item>
<item>
<title>Fosun Pharma Received NMPA Approval for Wan Ti Le (Tenapanor Hydrochloride Tablets)</title>
<link>https://6ix.com/company/shanghai-fosun-pharmaceutical-group-co-ltd/news/fosun-pharma-received-nmpa-approval-103300449</link>
<guid isPermaLink="true">https://6ix.com/company/shanghai-fosun-pharmaceutical-group-co-ltd/news/fosun-pharma-received-nmpa-approval-103300449</guid>
<pubDate>Wed, 26 Feb 2025 10:33:00 GMT</pubDate>
<description>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) announced that its holding subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. ("Fosun Pharma Industrial"), has received approval from the National Medical Products Administration ("NMPA") for the New Drug Application ("NDA") for Tenapanor Hydrochloride Tablets (Chinese trade name: Wan Ti Le, the "New Drug"), an innovative phosphate absorption inhibitor with a novel mechanism, w</description>
</item>
<item>
<title>Fosun Pharmaceutical Deeply Embraces AI, Self-developed PharmAID Decision Intelligence Platform Boosts Efficient Innovation</title>
<link>https://6ix.com/company/shanghai-fosun-pharmaceutical-group-co-ltd/news/fosun-pharmaceutical-deeply-embraces-ai-082200889</link>
<guid isPermaLink="true">https://6ix.com/company/shanghai-fosun-pharmaceutical-group-co-ltd/news/fosun-pharmaceutical-deeply-embraces-ai-082200889</guid>
<pubDate>Mon, 17 Feb 2025 08:22:00 GMT</pubDate>
<description>Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovation-driven pharmaceutical and healthcare group, Fosun Pharma places great emphasis on the transformative potential of AI technology in the pharmaceutical and healthcare sectors. The company actively embraces AI technology, deploying it in areas such as drug research and development, medical imaging, and precision medicine through both independe</description>
</item>
</channel>
</rss>